In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer

• Main Authors: Xiao Ling Ni (Author), Long Xia Chen (Author), Heng Zhang (Author), Bo Yang (Author), Shan Xu (Author), Min Wu (Author), Jing Liu (Author), Ling Lin Yang (Author), Yue Chen (Author), Shao Zhi Fu (Author), Jing Bo Wu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an anticancer drug. It is an accepted opinion that modifying GEF strong hydrophobicity and poor bioavailability would not only enhance its antitumor effects, but also reduce its side effects. In this stu...